Pop superstar Harry Styles once dog sat for 'The Crown' actress Emma Corrin so she could go out for dinner.
Pop superstar Harry Styles once dog sat for 'The Crown' actress Emma Corrin so she could go out for dinner.
Lion Electric expects to receive about $500 million of net cash proceeds from the deal, it said, adding the combined company was expected to be listed on the New York Stock Exchange under the symbol "LEV". The company said it would use the proceeds to fund the expansion of its U.S. manufacturing capacity, the development of advanced battery systems and the construction of a battery system assembly factory. Lion Electric's shareholders are expected to hold about 70% of the combined company's common equity after the deal is closed, assuming no redemptions from Northern Genesis' shareholders.
OPEC oil output rose for a fifth month in November, a Reuters survey found, as increased Libyan production offset full adherence by other producers to cuts agreed in an OPEC-led supply deal. OPEC, Russia and their allies, a group known as OPEC+, are gathering virtually on Monday and Tuesday and will consider whether to extend existing curbs due to weak demand or increase output gradually from January, sources say. "OPEC+ seem unable to reach agreement, at least in the run-up to today's meeting," said Eugen Weinberg of Commerzbank.
Dublin, Nov. 30, 2020 (GLOBE NEWSWIRE) -- The "Europe C5ISR Systems Market 2020-2030 by Solution, Platform (Land, Airborne, Naval, Space), Application, End User (Defense, Commercial), and Country: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering. Europe C5ISR systems market reached $23.9 billion in 2019 and will grow by 3.1% annually over 2020-2030 owing to the rising need for anti-terrorism and defense modernization.This report is based on a comprehensive research of the entire Europe C5ISR systems market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.In-depth qualitative analyses include identification and investigation of the following aspects: Market StructureGrowth DriversRestraints and ChallengesEmerging Product Trends & Market OpportunitiesPorter's Five Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe C5ISR systems market in every aspect of the classification from perspectives of Solution, Platform, Application, End User, and Country.Detailed analysis and annual revenue of each national market are available for 2019-2030. The breakdown of key national markets by Platform, Application, and End User over the forecast years are also included.The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.Specifically, potential risks associated with investing in Europe C5ISR systems market are assayed quantitatively and qualitatively through a Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.Key Topics Covered: 1 Introduction1.1 Industry Definition and Research Scope1.1.1 Industry Definition1.1.2 Research Scope1.2 Research Methodology1.2.1 Overview of Market Research Methodology1.2.2 Market Assumption1.2.3 Secondary Data1.2.4 Primary Data1.2.5 Data Filtration and Model Design1.2.6 Market Size/Share Estimation1.2.7 Research Limitations1.3 Executive Summary2 Market Overview and Dynamics2.1 Market Size and Forecast2.1.1 Impact of COVID-19 on the Market2.2 Major Growth Drivers2.3 Market Restraints and Challenges2.4 Emerging Opportunities and Market Trends2.5 Porter's five Forces Analysis3 Segmentation of Europe Market by Solution3.1 Market Overview by Solution3.2 Product3.3 Services4 Segmentation of Europe Market by Platform4.1 Market Overview by Platform4.2 Land-based Platform4.3 Airborne-based Platform4.4 Naval-based Platform4.5 Space-based Platform5 Segmentation of Europe Market by Application5.1 Market Overview by Application5.2 Intelligence, Surveillance, and Reconnaissance (ISR)5.3 Communication5.4 Command and Control5.5 Combat Systems5.6 Computers5.7 Electronic Warfare6 Segmentation of Europe Market by End User6.1 Market Overview by End User6.2 Defense Industry6.2.1 Military6.2.2 Homeland Security6.3 Commercial Sector6.3.1 Critical Infrastructure6.3.2 Commercial Space7 European Market 2019-2030 by Country7.1 Overview of European Market7.2 Germany7.3 UK7.4 France7.5 Spain7.6 Italy7.7 Russia7.8 Rest of European Market8 Competitive Landscape8.1 Overview of Key Vendors8.2 New Product Launch, Partnership, Investment, and M&A8.3 Company Profiles Airbus S.A.SBAE SystemsCACI International Inc.Collins AerospaceElbit Systems Ltd.General DynamicsHarris CorporationHuntington Ingalls Industries, Inc.Israel Aerospace Industries Ltd.Kratos Defense & Security Solutions, Inc.L3 Technologies, Inc.Leonardo SpALockheed Martin CorporationNorthrop Grumman CorporationRaytheon CompanyReutech Radar SystemsRheinmetall GroupSaab ABThales GroupThe Boeing Company 9 Investing in Europe Market: Risk Assessment and Management9.1 Risk Evaluation of Europe Market9.2 Critical Success Factors (CSFs)For more information about this report visit https://www.researchandmarkets.com/r/z1h7fc Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
From Shark kitchen appliances to TVs, these are the deals worth snapping up before the event ends
Summary “EU5 Clot Management Procedures Outlook to 2025” is a comprehensive databook report, covering key procedures data on the EU5 Clot Management Procedures. The databook report provides procedure volumes within segments - Inferior Vena Cava Filters (IVCF) Procedures and Thrombectomy Procedures.New York, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "EU5 Clot Management Procedures Outlook to 2025 - Inferior Vena Cava Filters (IVCF) Procedures and Thrombectomy Procedures" - https://www.reportlinker.com/p05993101/?utm_source=GNW The EU5 Clot Management Procedures report provides key information and data on - - Procedure volume data for Clot Management Procedures related to the country. Data is provided from 2015 to 2025. Scope EU5 Clot Management Procedures is segmented as follows - - Inferior Vena Cava Filters (IVCF) Procedures - Thrombectomy Procedures Reasons to Buy The EU5 Clot Management Procedures report helps you to develop - - Business strategies by identifying the key segments poised for strong growth in the future. - Market-entry and market expansion strategies. - Develop investment strategies by identifying the key segments expected to register strong growth in the near future.Read the full report: https://www.reportlinker.com/p05993101/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
From Shark kitchen appliances to TVs, these are the deals worth snapping up before the event ends
CNH Industrial has set up a five-year collaboration with Microsoft and Accenture to help it to develop "smart" and connected industrial vehicles, the Italian-American vehicle and equipment maker said on Monday. The programme, part of CNH Industrial's digital transformation plans, is expected to help the group "achieve significant revenue growth", the maker of farm machinery, Iveco commercial vehicles, construction equipment and powertrains said in a statement. The collaboration is mainly focused on setting up a global network of digital hubs, in Europe, the United States, Brazil and India, CNH said without providing financial details of the agreement.
Some people will be excited to see Bitcoin heading for $20,000 again, but I'd much rather invest in UK shares to fund a comfortable retirement. The post Bitcoin ‘to hit $20,000’ by Christmas! Who cares? I’m buying UK shares to retire rich appeared first on The Motley Fool UK.
U.S. tech giants Amazon and Apple have not signed up to a new French initiative to get global tech companies to publicly commit to principles including paying their fair share of taxes, government officials said on Monday. French President Emmanuel Macron has sought for the past three years to cajole tech giants into collaborating with governments on a series of global challenges such as fighting hate speech online, preserving privacy or contributing to state coffers. Amid a public outcry about technology groups' good fortunes during the coronavirus pandemic this year, Macron's advisers said on Monday that the president had asked tech companies to sign up to a new initiative called "Tech for Good Call" underlining principles for the post-COVID world.
It’s no secret that Apple products rarely ever go on sale (if at all). This Verizon Wireless sale, which ends today (Nov. 30, 2020) sees the 2019-released Apple device discounted to $299.99. While the iPhone 12 four-phone lineup was recently unveiled, the iPhone 11 still remains a customer favorite and a top-seller among the Apple devices released over the past few years.
DGAP-News: CureVac / Key word(s): 9 Month figures/Research Update 30.11.2020 / 13:20 The issuer is solely responsible for the content of this announcement. CureVac Announces Financial Results and Business Updates for the Third Quarter and First Nine Months of 2020 - COVID-19 prophylactic vaccine candidate: CVnCoV on track for advanced clinical testing - Interim Phase 1 data showed generally good tolerability for CVnCoV and strong antibody responses in addition to first indication of T cell activation - Stability confirmed for at least three months at standard refrigerator temperature and for up to 24 hours at room temperature - Pivotal Phase 2b/3 to be initiated shortly with 12µg dose - Agreement with European Commission to supply 225 million doses of CVnCoV and an option for an additional 180 million doses - Building a strong European manufacturing network to supply up to 300 million doses by end of 2021 and up to 600 million doses by the end of 2022 - Phase 1 results for oncology lead candidate, CV8102, confirm tolerability and responses in additional cancer indication - Financials: Cash position of €892 million as of September 30, 2020 TÜBINGEN, Germany/ BOSTON, USA - November 30, 2020 - CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced business updates and financial results for the third quarter and first nine months of 2020. "The first nine months of 2020 have been a transformative time for us at CureVac and also for the world around us," said Franz-Werner Haas, Chief Executive Officer of CureVac. "From the very start of the year, we made it a priority to address COVID-19. Over the first nine months of 2020, we have remained focused on the development of our mRNA-based vaccine candidate to help stop the spread of this severe disease. Our team's tremendous efforts were reflected in the positive Phase 1 interim data in early November as well as positive stability data, which indicates that our vaccine remains stable for at least three months at refrigerator temperature, and up to 24 hours at room temperature. These advancements, combined with our recent Advanced Purchase Agreement with the European Commission to supply 225 million doses of CVnCoV and an option for an additional 180 million doses, are highly promising for the anticipated large-scale vaccination efforts." "The achievement of our financial milestones to date in 2020 has put us in a favorable financial position," said Pierre Kemula, Chief Financial Officer of CureVac. "Proceeds of our successful IPO, additional investments and a grant from the German government allow us to expand the business, advance the clinical development of our COVID-19 vaccine candidate, CVnCoV, and support the ramp up of our manufacturing capacity in the coming months. For the remainder of 2020 and moving into 2021, we are focused on supporting CVnCoV commercialization and developing our unique technology platform across our clinical pipeline." Selected Business Updates for the Third Quarter and First Nine Months of 2020 Prophylactic Vaccines CVnCoV - Covid-19 Vaccine Candidate Phase 1 In June 2020, CureVac entered into a clinical Phase 1 dose escalation trial at clinical sites in Germany and Belgium to assess safety, reactogenicity and immunogenicity of CVnCoV. On November 10, 2020, the company reported detailed interim data based on more than 250 study participants tested in the dose range of 2µg to 12µg. The interim data showed that CVnCoV was generally well tolerated and induced strong binding and virus-neutralizing antibody responses across all tested doses. First indication of T cell activation was detected, and full T cell analysis will follow before the end of 2020. The quality of the immune response was found to be comparable to recovered COVID-19 patients, mimicking the immune response after natural COVID-19 infection. The data support advancement of the 12µg dose into a pivotal Phase 2b/3 trial. Detailed data can be accessed through a manuscript available on the medRxiv pre-print server. Phase 2a In September 2020, CureVac entered into a clinical Phase 2a study in Peru and Panama to further expand the clinical database of CVnCoV in a geographical environment with a high incidence of COVID-19 infection. The study includes individuals between 18 and 60 years old, but focuses on adults older than 60 years to further confirm safety and evaluate reactogenicity in this age group. The study will enroll approximately 690 individuals and includes testing at the 12µg dose. Phase 2b/3 Contingent on regulatory approval, CureVac plans to initiate a pivotal Phase 2b/3 study of more than 35,000 individuals shortly. The Phase 2b component will assess safety, reactogenicity and immunogenicity in study participants stratified according to age (>18 and >60 years old), initially at clinical testing sites in Europe and South America. The Phase 3 component will further assess safety and efficacy. If CureVac gains authorization to initiate the pivotal trial, an interim analysis could be carried out within the first quarter of 2021. Stability Study On November 12, 2020, CureVac announced initial data from its ongoing CVnCoV stability study. The data shows that CVnCoV remained stable and within defined analytical specifications for at least three months when stored at a standard refrigerator temperature of +5 C (+41 F), and for up to 24 hours at room temperature as a ready-to-use vaccine. The stability profile has the potential to be compatible with existing standard cold chain logistics. This will support large-scale vaccination efforts by enabling decentralized storage and positively impacting immunization cost and waste. The stability study is ongoing with the goal to further evaluate the potential for a longer commercial product shelf-life. Commercialization of COVID-19 vaccine candidate, CVnCoV On November 17, 2020, the European Commission announced the approval of a contract for the initial purchase of 225 million doses of CureVac's COVID-19 vaccine candidate, CVnCoV, including the option to request an additional 180 million doses on behalf of the European Union member states. CureVac is the fifth company to finalize an agreement with the European Commission. The doses will be supplied once CVnCoV has proven to be safe and effective against COVID-19. CureVac will receive an upfront payment to support the advanced clinical development of CVnCoV and the current expansion of its manufacturing network, as well as market launch and supply preparations. Manufacturing of COVID-19 vaccine candidate, CVnCoV CureVac currently operates three Good Manufacturing Practice (GMP) certified suites. Capacity of the third GMP suite is currently dedicated to the COVID-19 vaccine candidate, CVnCoV, to supply the ongoing Phase 1 and Phase 2a clinical trials, the planned pivotal Phase 2b/3 trial, as well as potential early commercialization activities. A fourth GMP facility is currently in development to handle all manufacturing steps from starting material to formulation, operating at industry scale to support future commercial launches. On July 6, 2020, CureVac announced the closing of a €75 million loan agreement with the European Investment Bank to support the company's efforts to expand existing GMP-certified production capabilities and accelerate the completion of the fourth production site. On November 17, 2020, CureVac announced that it is building an integrated European vaccine manufacturing network with highly experienced Contract Development and Manufacturing Organization (CDMO) partners for each major manufacturing step. This strategy further strengthens the clinical development of CVnCoV, the preparations for a potential launch and rapid market supply. Based on the selection of a 12µg dose to move into advanced clinical trials, the manufacturing network will significantly increase the existing capacity to provide up to 300 million doses of CVnCoV in 2021 and up to 600 million doses in 2022. GlaxoSmithKline Collaboration Agreement In July 2020, CureVac entered into a Collaboration and License Agreement with GSK, one of the industry's leading vaccine experts. Within the scope of the agreement, the companies will combine their respective mRNA expertise to collaborate on development opportunities across a range of infectious disease pathogens, selected with the potential to best leverage the advantages of this platform technology, while addressing significant unmet medical need and economic burden. The strategic technology collaboration encompasses mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens. Under the terms of the deal, GSK made an equity investment in CureVac of €150m and an upfront cash payment of €120m. CureVac is eligible to receive development and regulatory milestone payments, commercial milestone payments and tiered royalties on product sales. Oncology CV8102 - Cancer immuno-modulator in solid tumors Phase 1 On November 9 at the Society for Immunotherapy of Cancer (SITC) conference, CureVac presented updated data from the ongoing Phase 1 dose-escalation study of its lead oncology product candidate. The study assesses tolerability as well as activity of CV8102 in the dose range of 25 to 900µg as a single agent, and in combination with systemic anti-PD-1 antibodies for the intra-tumoral treatment of four types of solid tumors: cutaneous melanoma, adenoid cystic carcinoma, squamous cell carcinoma of skin and squamous cell carcinoma of head and neck. CV8102 showed an acceptable tolerability with adverse events mainly accumulating around mild to moderate fever, fatigue, chills and headache. Following a first data presentation at the American Society of Clinical Oncology (ASCO) in April 2020, the data presented at SITC (Cut-off was October 5, 2020) featured 29 patients treated with CV8102 as a single agent and 21 patients treated with CV8102 in combination with anti-PD-1 antibodies. The formerly observed objective tumor responses in two melanoma patients, and two additional patients with a stable disease, including shrinkage of non-injected lesions in the single agent cohort, were extended by a new partial response observed in a patient with cutaneous squamous cell carcinoma pre-treated with anti-PD-1. This observation expanded activity from melanoma into a second indication. Additionally, the first RECIST response in the PD-1 combination cohort was observed in a PD-1 refractory melanoma patient with regression of non-injected lesions in the lung and liver. CureVac plans to initiate an expansion cohort in early 2021. Financial Update for the Third Quarter and First Nine Months of 2020 Cash Position Cash increased from €30.7 million as of December 31, 2019 to €892.4 million as of September 30, 2020, mainly due to the €559.3 million raised in the 2020 Private Investment in July 2020, along with €192.9 million in proceeds, net of underwriting discounts and commission, from CureVac's initial public offering (IPO) on the Nasdaq in August 2020, €100 million from the August 2020 concurrent private placement to Dietmar Hopp and the €120 million non-refundable upfront payment received from GSK. Revenues Revenue was €5.2 million and €42.8 million for the three and nine months ended September 30, 2020, respectively, representing an increase of €4.1 million and €32.2 million, or 371% and 304%, from €1.1 million and €10.6 million for the same periods in 2019, respectively. These increases were primarily driven by the following events: in July 2020, GlaxoSmithKline plc (GSK) and CureVac signed a strategic collaboration agreement for the research, development, manufacturing and commercialization of mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens. In addition to an equity investment of €150 million, made as part of the 2020 Private Investment, GSK made a non-refundable upfront payment of €120 million, which has been deferred and recognized as a contract liability. For the three months ending September 30, 2020, €3.7 million was released from contract liabilities and recognized as revenues. In June 2020, CureVac and Eli Lilly terminated the License and Collaboration Agreement dated November 29, 2017, as well as the Early Clinical Supply Agreement dated July 5, 2018 and related Quality Agreement dated June 29, 2018. As a result, on the termination date, €33.1 million in contract liabilities from an upfront payment was recognized as revenue as no further associated performance obligations remained. Operating result Operating loss was €36.8 million and €63.2 million for the three and nine months ended September 30, 2020, respectively, representing an increase of €17.6 million and a decrease of €1.2 million, or an increase of 92% and a decrease of 2%, from -€19.2 million and -€64.4 million for the same periods in 2019, respectively. The decreased operating loss was mainly driven by recognition of the €33.1 million in contract liabilities upon termination of the Eli Lilly collaboration, offset by higher research and development costs, primarily due to high costs for CVnCoV R&D activities, including research material manufacturing expenses, which began in 2020. This decrease was partially offset by a decrease in cost of sales during both of these periods in 2020 as compared to 2019 due to lower set-up activities and lower product manufacturing for our collaboration partners. The increase of the other operating income was driven by higher cost reimbursements received from CEPI. Financial Result Financial result was €0.1 million and -€9.4 million for the three and nine months ended September 30, 2020, respectively, representing no change compared to the first three months in the same period of 2019 and a decrease of €9.6 million from €0.2 million for the nine months ended in September 2019, respectively. Financial result for the nine months ended September 30, 2020, contains mainly interest for the convertible loans, which were fully repaid, including interest, in August 2020, partially offset by foreign exchange gains. Net loss Net loss was €36.8 million and €71.0 million for three and nine months ended September 30, 2020, or a loss of €0.24 and €0.61 per share (on a basic and diluted basis), respectively, compared to a net loss of €18.4 million and €63.9 million, or loss of €0.19 and €0.66 per share (on a basic and diluted basis), in the same respective periods of 2019. Conference Call and Webcast CureVac will host an analyst and investor webcast and conference call on Monday, November 30, 2020, at 4:00 p.m. CET / 10:00 a.m. EST). The live conference call dial-in details and webcast link can be accessed via the Investor Relations section of the CureVac homepage at https://www.curevac.com/en/newsroom/events/ Corresponding presentation slides will be posted shortly before the start of the webcast. A replay will be made available at this website after the event. About CVnCoV CureVac began development of its mRNA-based COVID-19 vaccine candidate in January 2020. The compound is an optimized, non-chemically modified mRNA, encoding the pre-fusion stabilized full-length spike protein of the SARS-CoV-2 virus. Phase 1 and 2a clinical trials of CVnCoV began in June and September 2020, respectively. Phase 1 interim data reported in November 2020 showed that CVnCoV was generally well tolerated across all tested doses and induced strong antibody responses in addition to first indication of T cell activation. The quality of immune response was comparable to recovered COVID-19 patients, mimicking the immune response after natural COVID-19 infection. The data support CureVac's decision to advance a 12µg dose in its upcoming pivotal Phase 2b/3 study, which CureVac plans to initiate before the end of 2020. Clinical trial material is provided by the company's substantial production capacities for mRNA vaccines at its headquarters in Tübingen, supported by the current expansion of manufacturing capacities to allow for broad-scale manufacturing of CVnCoV for potential commercial supply preparedness. About CureVac CureVac is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. Based on its proprietary technology, the company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered in Tübingen, Germany, and employs more than 500 people at its sites in Tübingen, Frankfurt, and Boston, USA. Further information can be found at www.curevac.com. CureVac Media Contact Thorsten Schüller, Vice President Communications CureVac, Tübingen, Germany T: +49 7071 9883-1577 email@example.com CureVac Investor Relations Contact Dr. Sarah Fakih, Vice President Investor Relations CureVac, Tübingen, Germany T: +49 7071 9883-1298 M: +49 160 90 496949 firstname.lastname@example.org Forward-Looking Statements This press release contains statements that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac (the "company") regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the company's strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would," "could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov. CureVac N.V. Condensed Consolidated Balance Sheet September 30, December 31, (in € thousands) 2020 2019 (unaudited) Assets Non-current assets Intangible assets 10.138 5.698 Property, plant and equipment 59.364 48.075 Right-of-use assets 34.693 13.611 Other assets 2.147 6.061 Deferred tax assets 65 - Total non-current assets 106.407 73.445 Current assets Inventories 1.426 6.197 Trade receivables - 15.690 Contract assets 535 1.463 Other financial assets 1.129 1.458 Prepaid expenses and other assets 20.011 1.683 Cash and cash equivalents 892.399 30.684 Total current assets 915.500 57.175 Total assets 1.021.907 130.620 Equity and liabilities Equity Issued capital 21.560 11.603 Capital reserve 1.326.766 461.520 Accumulated deficit (586.922) (515.947) Other comprehensive income (54) 22 Total equity 761.350 (42.802) Non-current liabilities Convertible loans - 65.018 Lease liabilities 27.724 12.126 Contract liabilities 121.778 66.040 Deferred tax liabilities - 1.623 Other liabilities 530 529 Total non-current liabilities 150.032 145.336 Current liabilities Lease liabilities 2.921 2.004 Trade and other payables 50.225 6.475 Other liabilities 27.052 12.015 Income taxes payable 130 111 Contract liabilities 30.197 7.481 Total current liabilities 110.525 28.086 Total liabilities 260.557 173.422 Total equity and liabilities 1.021.907 130.620 CureVac N.V. Condensed Consolidated Profit and Loss Statement Nine Months ended September 30, Three Months ended September 30, 2020 2019 2020 2019 (in € thousands) (unaudited) (unaudited) Revenue 42.830 10.600 5.162 1.096 Cost of sales (7.049) (18.872) (1.973) (6.999) Selling and distribution expenses (809) (485) 200 24 Research and development expenses (76.337) (30.665) (34.570) (5.349) General and administrative expenses (33.147) (28.504) (9.422) (9.124) Other operating income 11.695 3.838 3.964 1.333 Other operating expenses (357) (339) (119) (126) Operating loss (63.174) (64.427) (36.758) (19.145) Finance income 5.103 3.133 3.873 1.422 Finance expenses (14.519) (2.924) (3.805) (1.281) Loss before income tax (72.590) (64.218) (36.690) (19.004) Income tax benefit/ (expense) 1.615 335 (144) 644 Net loss for the period (70.975) (63.883) (36.834) (18.360) 30.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Noom, the leading digital health platform focused on behavior science, today announced several key executive hires to further accelerate the professionalization and commercialization of the company’s mission to help more people live healthier lives.
Check our guide to the top Tempur-Pedic deals for Cyber Monday 2020, featuring all the best deals on Tempur-Pedic mattresses, pillows and toppers
Save on Dyson vacuum deals at the Cyber Monday 2020 sale, featuring all the latest Dyson V7, Cyclone V10 & V11 cordless vacuum cleaner offers
On Cyber Monday, we bring you the best deals across tech, toys and home appliances
The Shared Services Market will grow by $ 152.38 bn during 2020-2024
Köln rejoice in 'miracle of Dortmund' sealed by Haaland's incredible missTwo almost identical goals by Ellyes Skhiri and a last-minute blunder by Haaland ended a 267-day wait for a Bundesliga win
Poland's biggest oil refiner PKN Orlen expects to invest around 140 billion zlotys (28.13 billion pounds) over the next ten years as it shifts to clean energy sources rather than oil refining, it said in its strategy update on Monday. The company said in September that it plans to become climate neutral in the next 30 years, although Poland is the only European Union state which has not pledged to cut emissions to zero by 2050. "We are preparing for changes, especially that oil refining will be becoming less significant," PKN Orlen Chief Executive Daniel Obajtek said, adding that renewable energy sources and petrochemicals will be major drivers of the group's core profit (EBITDA).
There are so many reasons not to back any agreement brought forward by the PM that it is hard to know where to start. So let’s look at the arguments being made by those who think they should
Dublin, Nov. 30, 2020 (GLOBE NEWSWIRE) -- The "Indian Tankless Water Heater Market 2020-2026" report has been added to ResearchAndMarkets.com's offering. The Indian tankless water heater market is estimated to grow significantly during the forecast period. Moreover, increasing the installation of a solar water heating system is propelling the growth of the market in the region. The development of contemporary renewable heat in India has been uncertain, accounted for a 14% growth between 2007 and 2015. The IEA (International Energy Agency) Technology Collaboration Programme on Solar Heating and Cooling, increases the number of systems installations in India by 26% in 2017. According to the IEA, the solar thermal capacity that is mostly used for water heating projected significant growth in India. The total solar thermal capacity in India accounted for 2.8 GWth in 2010 and it is increased to 7.7 GWth in 2017. India has the sixth-largest installed capacity for solar thermal across the globe.The Indian market for the tankless water heater is further classified on the basis of product type and application. Based on the product type, the market is further classified into an electric water heater and gas water heater. The electric water heater segment is projected to have significant growth in the Indian tankless water heater market. The growing demand for tankless electric water heater in the residential and commercial sectors due to convenience and cost-effectiveness is further projected to contribute to the growth of the segmental market. On the basis of application, the market is further segregated into residential and commercial. The residential application is projected to hold a considerable share in the Indian tankless water heater market.The companies which are contributing to the growth of the Indian tankless water heater market include Bajaj Electricals Ltd., Crompton Greaves Consumer Electricals Ltd., Haier Electronics Group Co., Ltd., Havells India Ltd., and others. Product launch, merger, and acquisition, collaborations with government, and technological advancements through which market players are considerably contributing to the market growth to stay competitive in the market.Research MethodologyThe market study of the Indian tankless water heater market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors.Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.Secondary Sources Include Financial reports of companies involved in the market.Whitepapers, research-papers, and news blogs.Company websites and their product catalog. The report is intended for tankless water heater providers, end-user for overall market analysis, and competitive analysis. The report provides an in-depth analysis of pricing, market size, intended quality of the product preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.The Report Covers Comprehensive research methodology of the Indian tankless water heater market.This report also includes a detailed and extensive market overview with key analyst insights.An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.Analysis of regional regulations and other government policies impacting the Indian tankless water heater market.Insights about market determinants which are stimulating the Indian tankless water heater market.Detailed and extensive market segments with regional distribution of forecasted revenues.Extensive profiles and recent developments of market players. Key Topics Covered: 1. Report Summary2. Market Overview and Insights2.1. Scope of the Report2.2. Analyst Insight & Current Market Trends2.2.1. Key Findings2.2.2. Recommendations2.2.3. Conclusion3. Market Determinants3.1. Motivators3.2. Restraints3.3. Opportunities4. Market Segmentation4.1. Indian Tankless Water Heater Market by Product Type4.1.1. Electric Water Heater4.1.2. Gas Water Heater4.2. Indian Tankless Water Heater Market by Application4.2.1. Residential4.2.2. Commercial5. Company Profiles5.1. A.O. Smith Corp.5.2. Bajaj Electricals Ltd.5.3. Crompton Greaves Consumer Electricals Ltd.5.4. General Electric Co.5.5. Haier Electronics Group Co., Ltd.5.6. Havells India Ltd.5.7. Robert Bosch GmbH5.8. Rheem Manufacturing Company, Inc.5.9. Rinnai Corp.5.10. Racold Thermo Pvt. Ltd.5.11. Venus home applianceFor more information about this report visit https://www.researchandmarkets.com/r/1vuv02 Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900